10 research outputs found
Integrative Bioinformatic Analysis of a Greek Epidemiological Cohort Provides Insight into the Pathogenesis of Primary Cutaneous Melanoma
Part 1: Medical Artificial Intelligence Modeling (MAIM)International audienceMelanoma is the most lethal type of skin cancer. In this study for the first time we analyze a Greek cohort of primary cutaneous melanoma biopsies, subjected to whole exome sequencing, in order to derive their mutational profile landscape. Moreover, in the context of big data analytical methodologies, we integrated the results of the exome sequencing analysis with transcriptomic data of cutaneous melanoma from GEO, in an attempt to perform a multi-layered analysis and infer a tentative disease network for primary melanoma pathogenesis. The purpose of this research is to incorporate different levels of molecular data, so as to expand our understanding of cutaneous melanoma and the broader molecular network implicated with this type of cancer. Overall, we showed that the results of the integrative analysis offer deeper insight in the underlying mechanisms affected by melanoma and could potentially contribute to the valuable effective epidemiological characterization of this disease
Necrosis and apoptotic index as prognostic factors in non-small cell lung carcinoma: a review
Necrosis and apoptosis represent two pathogenetically distinct types of
cell death. Necrosis is associated with pathologic conditions while
apoptosis is a physiological process of programmed cell death, which is
associated with normal tissue growth and is frequently impaired in
various forms of cancer. Tumor necrosis and apoptotic index (AI) have
been previously evaluated as prognostic biomarkers in lung cancer, but
their exact clinical value remains unclear. The aim of this study was to
perform a systematic review of the MEDLINE literature on the prognostic
significance of these histopathological markers in patients with
non-small cell lung carcinoma (NSCLC). Although a substantial body of
evidence suggests that tumor necrosis may be a strong predictor of
aggressive tumor behavior and reduced survival in patients with NSCLC,
the independent prognostic value of this biomarker remains to be firmly
established. Furthermore, previous data on the prognostic significance
of apoptotic index in NSCLC are relatively limited and largely
controversial. More prospective studies are necessary in order to
further validate tumor necrosis and AI as prognostic markers in NSCLC
Primary Malignant Melanoma of the Cervix: A Case Report and a Review of the Literature
Background. Gynecologic melanomas are extremely rare malignancies, and primary malignant melanoma of the cervix (PMMC) is the rarest among them all, with less than 100 cases reported so far. Although some conditions have been correlated with the pathogenesis of this entity, no specific risk factor has been yet identified, with vaginal bleeding being the most common symptoms. The diagnosis is based on physical examination with speculum assessment and cytologic and histopathologic findings accompanied with immunohistochemical staining of lesion’s biopsies. Case Presentation. We report a case of PMMC in a 34-year-old para-2 patient, among the youngest cases of PMMC reported, that presented to our clinic for routine examination. Gynecologic examination demonstrated a dark, heavily fully pigmented cervical growth completely covering the entire external cervical os. Biopsy obtained and showed malignant melanoma. She underwent radical hysterectomy with bilateral salpingo-oophorectomy and pelvic lymphadenectomy. The pathological diagnosis was FIGO stage IB1 PMMC. Despite 2 courses of anti-PD-1 antibody (Nivolumab) treatment, the patient passed away 13 months after diagnosis (12 months after surgery). Conclusions. Early diagnosis and subsequently early treatment are of high importance regarding patients’ prognosis and survival. No standardized protocols or treatment guidelines specific for this rare cancer have been issued; thus, clinicians are called to assess each case individually. Current treatment options are based on surgical excision mostly with radical hysterectomy, but in advanced or recurrent state of the disease, other treatment modalities, such as chemotherapy, radiotherapy, and immunotherapy, can be employed. Prognosis for these patients is very poor, and survival rate remains extremely low, with the median OS reported being less than 2 years. Reporting and publishing of such cases are both of paramount importance for the better understanding of this uncommon cervical malignancy, and further biological and clinical investigations are required for more suitable and effective therapies to be determined. A new staging system, specific to PMMC, could be of great use for the better correlation of the disease’s stage and prognosis of these patients
Experimental Osteomyelitis Caused by Methicillin-Resistant Staphylococcus aureus Treated with a Polylactide Carrier Releasing Linezolid
Background: The effectiveness of a new delivery system consisting of
polymerized dilactide (PLA) with incorporated linezolid was investigated
in a rabbit model as a means of treating methicillin-resistant
Staphylococcus aureus (MRSA) osteomyelitis.
Methods: The PLA-linezolid system was prepared after thorough stirring
of PLA with linezolid at a 10: 1 ratio. Experimental osteomyelitis was
established in 40 rabbits by a modification of the Norden model with
MRSA as the test isolate. After a hole had been drilled in the upper
right femur, the isolate was inoculated using a thin needle working as a
foreign body. At three weeks, the needle was removed and cultured, and
the PLA-linezolid system was implanted in half the animals (group B);
the remaining half was the control group (group A). Animals were
sacrificed at regular intervals; tissue around the site of implantation
was examined for pathologic changes and cultured quantitatively.
Results: The prepared system eluted linezolid in vitro at concentrations
much greater than the minimum inhibitory concentration (MIC) of the test
pathogen for 11 days. At three weeks after inoculation of the test
isolate, all animals had osteomyelitis. By the sixth week, bacterial
growth from cancellous bone of group B was significantly lower than that
in group A. However, this effect was not maintained until the end of the
study (weeks 8 and 10), when the differences in bacterial growth in the
two groups were not significant.
Conclusion: Polymerized dilactide mixed with 10% linezolid achieved
partial arrest of the offending pathogen in an experimental model of
osteomyelitis caused by MRSA
High expression of BCL-2 predicts favorable outcome in non-small cell lung cancer patients with non squamous histology
Abstract Background Bcl-2 promotes cell survival by inhibiting adapters needed for the activation and cleavage of caspases thus blocking the proteolytic cascade that ultimately dismantles the cell. Bcl-2 has been investigated as a prognostic factor in non small cell lung cancer (NSCLC) patients with conflicting results. Methods Here, we quantitatively assessed Bcl-2 expression in two large and independent cohorts to investigate the impact of Bcl-2 on survival. AQUA®, a fluorescent-based method for analysis of in situ protein expression, was used to measure Bcl-2 protein levels and classify tumors by Bcl-2 expression in a cohort of 180 NSCLC patients. An independent cohort of 354 NSCLC patients was used to validate Bcl-2 classification and evaluate outcome. Results Fifty % and 52% of the cases were classified as high expressers in training and validation cohorts respectively. Squamous cell carcinomas were more likely to be high expressers compared to adenocarcinomas (63% vs. 45%, p = 0.002); Bcl-2 was not associated with other clinical or pathological characteristics. Survival analysis showed that patients with high BCL-2 expression had a longer median survival compared to low expressers (22 vs. 17.5 months, log rank p = 0.014) especially in the subset of non-squamous tumors (25 vs. 13.8 months, log rank p = 0.04). Multivariate analysis revealed an independent lower risk for all patients with Bcl-2 expressing tumors (HR = 0.53, 95% CI 0.37-0.75, p = 0.0003) and for patients with non-squamous tumors (HR = 0.5, 95% CI 0.31-0.81, p = 0.005). Conclusions Bcl-2 expression defines a subgroup of patients with a favorable outcome and may be useful for prognostic stratification of NSCLC patients.</p